- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis Severe Crohn disease, Complex refractory fistulising Crohn Disease Moderate to severe ulcerative colitis
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Infliximab – March 2025
Infliximab; Powder for I.V. infusion 100 mg; Ixifi®
Last updated
12 March 2025